Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Recursion Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Recursion Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -945.9%. For fiscal 2025 it was -863.4%, against -788.0% the year before. The highest annual figure on record is -601.0% in fiscal 2022.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -863.4% | −75.3 |
| FY2024 | Dec 31, 2024 | -788.0% | −52.0 |
| FY2023 | Dec 31, 2023 | -736.0% | −134.9 |
| FY2022 | Dec 31, 2022 | -601.0% | +1231.1 |
| FY2021 | Dec 31, 2021 | -1832.2% | +363.8 |
| FY2020 | Dec 31, 2020 | -2196.0% | +472.3 |
| FY2019 | Dec 31, 2019 | -2668.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1708.0% | −813.8 |
| Q1 FY2026 | Mar 31, 2026 | -1815.6% | −442.3 |
| Q4 FY2025 | Dec 31, 2025 | -304.2% | +3631.2 |
| Q3 FY2025 | Sep 30, 2025 | -3135.3% | −2767.9 |
| Q2 FY2025 | Jun 30, 2025 | -894.2% | −217.7 |
| Q1 FY2025 | Mar 31, 2025 | -1373.3% | −710.8 |
| Q4 FY2024 | Dec 31, 2024 | -3935.5% | −3081.6 |
| Q3 FY2024 | Sep 30, 2024 | -367.5% | +515.6 |
| Q2 FY2024 | Jun 30, 2024 | -676.6% | +19.9 |
| Q1 FY2024 | Mar 31, 2024 | -662.4% | −124.0 |
| Q4 FY2023 | Dec 31, 2023 | -853.9% | −433.5 |
| Q3 FY2023 | Sep 30, 2023 | -883.1% | −423.8 |
| Q2 FY2023 | Jun 30, 2023 | -696.4% | +157.9 |
| Q1 FY2023 | Mar 31, 2023 | -538.4% | +511.3 |
| Q4 FY2022 | Dec 31, 2022 | -420.4% | +2143.1 |
| Q3 FY2022 | Sep 30, 2022 | -459.3% | +1412.4 |
| Q2 FY2022 | Jun 30, 2022 | -854.3% | +848.4 |
| Q1 FY2022 | Mar 31, 2022 | -1049.7% | +149.3 |
| Q4 FY2021 | Dec 31, 2021 | -2563.5% | −1606.0 |
| Q3 FY2021 | Sep 30, 2021 | -1871.7% | +457.4 |
| Q2 FY2021 | Jun 30, 2021 | -1702.7% | +8481.7 |
| Q1 FY2021 | Mar 31, 2021 | -1198.9% | +29507.7 |
| Q4 FY2020 | Dec 31, 2020 | -957.5% | – |
| Q3 FY2020 | Sep 30, 2020 | -2329.1% | – |
| Q2 FY2020 | Jun 30, 2020 | -10184.4% | – |
| Q1 FY2020 | Mar 31, 2020 | -30706.7% | – |
See a number that looks wrong?